pSivida Corp. Form 10-Q Summary
Entity and period: The supplied filing is for pSivida Corp. and subsidiaries, not a registrant named EyePoint, Inc. It covers the three months ended September 30, 2014, the company’s fiscal first quarter, and was filed November 7, 2014. Financial amounts below are in U.S. dollars.
Business context
pSivida develops sustained-release drug-delivery technologies, principally for chronic eye diseases. Its lead independent candidate, Medidur, was in a pivotal Phase III trial for posterior uveitis. Its licensed product ILUVIEN was approved by the FDA for a restricted diabetic macular edema (DME) population on September 26, 2014; Alimera Sciences licenses and commercializes it.
Financial performance and liquidity
| Metric | Three months ended September 30, 2014 | Prior-year quarter |
|---|---|---|
| Total revenue | $25.307 million | $0.597 million |
| Operating expenses | $4.518 million | $4.315 million |
| Operating income (loss) | $20.789 million | $(3.718) million |
| Net income (loss) | $20.566 million | $(3.687) million |
| Diluted EPS | $0.67 | $(0.14) |
| Cash used in operations | $3.994 million | $3.777 million |
- Revenue and reported profit were dominated by a one-time $25.0 million ILUVIEN FDA approval milestone. The milestone was recognized in the quarter because collectability was considered reasonably assured; cash was received October 24, 2014. It should not be treated as recurring product revenue.
- Royalty income fell 47% to $226,000, which management attributed at least partly to lower Retisert sales and competition. Collaborative R&D revenue excluding the milestone remained small.
- R&D expense rose 11% to $2.784 million, primarily due to Medidur clinical-trial contractor costs and Tethadur preclinical work. General and administrative expense decreased 4% to $1.734 million.
- At September 30, cash and cash equivalents were $11.384 million and marketable securities were $2.924 million, totaling $14.308 million. Accounts and other receivables were $25.462 million, largely reflecting the milestone due from Alimera.
- Total liabilities were $7.938 million; the filing reports no borrowings or line of credit. Current assets were $40.685 million against current liabilities of $2.312 million. The quarter-end balance excludes the subsequent milestone cash receipt.
- Cash and cash equivalents declined by $3.950 million during the quarter. Operating cash use was $3.994 million; investing activities used $7,000 and financing provided $56,000.
Changes, outlook, and risks
- Compared with the prior-year quarter, pSivida moved from a net loss to substantial reported profit, primarily because of the FDA milestone rather than an improvement in recurring sales. Operating cash use increased by $217,000.
- Management estimated that quarter-end cash, cash equivalents and marketable securities, together with the $25.0 million milestone received in October, would fund current and planned operations into calendar 2017. This estimate excluded potential ILUVIEN net-profit participation and depended on assumptions about future spending and receipts.
- The company expected negative operating cash flows after the quarter ending December 31, 2014 until sufficient product revenues were generated. ILUVIEN’s U.S. commercial launch was expected in the first calendar quarter of 2015; pSivida said the timing and amount of any profit-share receipts were uncertain.
- Management planned to seek FDA approval for Medidur based on its ongoing Phase III trial plus supplemental inserter-use data, but the FDA might require a second Phase III trial, increasing time and cost. R&D spending on Medidur was expected to remain significant.
- Key risks included Alimera’s ability to finance and commercialize ILUVIEN, pricing and reimbursement, FAc-related eye side effects, declining Retisert royalties, clinical and regulatory uncertainty, and potential need for additional capital. The remaining ATM facility permitted up to $10.7 million of share sales as of September 30; future financing could dilute shareholders or be unavailable on favorable terms.
- Routine legal proceedings and claims were described as not expected to have a material effect. Management reported effective disclosure controls and no material changes in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer identity: the provided 10-Q names pSivida Corp., while the request metadata names EyePoint, Inc.
- Check subsequent filings for the October 24 receipt and use of the $25.0 million milestone, and distinguish it from recurring revenue and cash generation.
- Track ILUVIEN’s U.S. launch, sales, reimbursement, Alimera’s commercialization costs, and whether sales generate pSivida profit-share payments.
- Monitor Retisert royalty trends and the Medidur Phase III results and FDA feedback on whether one trial will suffice.
- Reassess the stated runway against actual operating cash burn, clinical spending, and any financing or dilution.